Ibrance approval cemented as competition comes into viewIn February 2015, Pfizer’s Ibrance (palbociclib) was granted accelerated approval by the FDA for treatment of newly diagnosed Share XIbrance approval cemented as competition comes into viewhttps://pharmaphorum.com/partner-content-oncology/ibrance-approval-cemented-competition-comes-view/
Does NEMO bring us a step closer in the fight against melanoma?Options for treatment in metastatic melanoma have increased significantly in terms of efficacy and reduction of mortality in Share XDoes NEMO bring us a step closer in the fight against melanoma?https://pharmaphorum.com/partner-content-oncology/nemo-bring-us-step-closer-fight-melanoma/
The HNSCC immunotherapy race is on – and it’s going to be closeWhile improper to compare life saving treatments to buses – the metaphor when it comes to head and Share XThe HNSCC immunotherapy race is on – and it’s going to be closehttps://pharmaphorum.com/partner-content-oncology/hnscc-immunotherapy-race-going-close/
Further Darzalex results extend hope for PFS in MyelomaEarlier this year (March), Johnson & Johnson announced that the randomized Phase III CASTOR trial (NCT02136134) achieved its Share XFurther Darzalex results extend hope for PFS in Myelomahttps://pharmaphorum.com/partner-content-oncology/further-darzalex-results-extend-hope-for-pfs-in-myeloma/
Positive PIII results for VYXEOS revealed at ASCOBuilding on the announcement made in March of this year, Celator Pharmaceuticals has today (June 4th) presented the Share XPositive PIII results for VYXEOS revealed at ASCOhttps://pharmaphorum.com/partner-content-oncology/positive-piii-results-for-vyxeos-revealed-at-asco/
What are the key presentations at ASCO 2016?The 2016 American Society of Clinical Oncology (ASCO) annual meeting starts today (3rd June), and it promises to Share XWhat are the key presentations at ASCO 2016?https://pharmaphorum.com/partner-content-oncology/what-are-the-key-presentations-at-asco-2016/
